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Background and PurposeaaLevetiracetam (LEV) is an antiepileptic drug (AED) that has fa-
vorable effects on cognition. Although neuropsychological studies have demonstrated these fa-
vorable outcomes on cognition, there are few electrophysiologic data describing the functional 
changes exerted by LEV. The purpose of this study was to determine the effects of LEV ad-
junctive therapy on the current-source density (CSD) in the high beta frequency band (22-30 
Hz) of EEG background activity in refractory partial epilepsy (RPE). 
MethodsaaWe conducted a 24-week, open-label, prospective study in 24 patients with RPE. 
Scalp electroencephalography and neuropsychological tests (NPTs) were conducted twice, once 
before the LEV trial and then again after 24 weeks of medication. 
ResultsaaThe CSD in the 22-30 Hz band of EEG background activity increased in the bila-
teral anterior cingulate gyri, left parahippocampal gyrus, and a small area of the right anterior 
parahippocampal gyrus after the LEV trial. Neither seizure freedom nor the dosage increment 
of LEV elicited meaningful CSD changes. Verbal memory and executive function were improv-
ed after the 24-week LEV trial. 
ConclusionsaaTo our knowledge, this is the first study to examine the changes in CSD in-
duced by LEV adjunctive therapy in RPE patients. The CSD changes and NPT results suggest 
that LEV enhances the activities of the neuronal networks in the prefrontal cortex and left hip-
pocampus.  J Clin Neurol  2009;5:178-185
 
Key Wordsaaelectroencephalography, current-source analysis, levetiracetam, adjunctive ther-
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Introduction 
 
Patients with epilepsy often experience cognitive dysfunc-
tion. Antiepileptic drugs (AEDs) can also adversely affect cog-
nitive function by suppressing neuronal excitability or enhanc-
ing inhibitory neurotransmission. In general, the effects on 
cognition are less severe with modern AEDs than with the 
“classic” AEDs, with the exception of topiramate (TPM) and 
zonisamide.
1-4 Levetiracetam (LEV) is one of the modern 
AEDs; it has been demonstrated to be effective in the treat-
ment of symptomatic and idiopathic epilepsy,
5,6 and has been 
reported to have no adverse effects on cognition. 
A recent randomized, double-blind, crossover study of LEV 
versus carbamazepine (CBZ) in healthy volunteers revealed 
better results on half of the neuropsychological measures un-
der LEV, whereas none of the results on the measures were 
superior under CBZ.
7 Two of four adjunctive trials of LEV in 
patients with refractory partial epilepsy (RPE) reported im-
proved cognitive function,
8,9 whereas other studies found no 
effect.
10,11 The mechanisms underlying the improvement in 
cognitive function by LEV remain unknown. It is thought 
that it may act by controlling seizures and suppressing epil-
eptiform discharges.
12 The pharmacological properties of LEV 
may include neuroprotective effects against brain insults.
13 
Thus, it would be useful to elucidate the mechanism of LEV-
induced improvements in cognitive function using electro-
physiology studies and/or neuroimaging. 
Electroencephalogram (EEG) studies of neurocognitive  
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function have focused on the frequency band over 20 Hz. It 
has been shown in human EEG studies that the cortical high-
frequency activity is topically enhanced in various cognitive 
processes.
14-17 Complex cognitive tasks ignite neuronal cell 
assemblies and activate loops of neuronal network. In the 
case of the language process, a loop between Broca’s region 
and Wernicke’s region is activated.
18 The neuronal oscilla-
tion is equivalent to a circulation frequency of 25-30 Hz. In 
contrast, higher-frequency oscillatory cortical activity, in the 
range 40-60 Hz, is seen in less widely dispersed cell assem-
blies.
19 The increase in gamma power synchronization of 
evoked gamma activity may indicate a general mechanism 
that enables transient associations between neuronal assem-
blies. The synchronized gamma activity also may be relevant 
to selective attention.
20  
It is difficult to establish the brain current source by visual 
inspection of multichannel EEG data, because many combi-
nations of current sources with various locations and streng-
ths in the brain may generate signals in the scalp electrodes. 
Current-source analysis (CSA) using digital EEG data can be 
used to directly measure neuronal activity. CSA uses mathe-
matical methods to analyze the electrical potentials on the 
scalp electrodes and to determine the exact location of cur-
rent sources.
21 
Low-resolution brain electromagnetic tomography (LOR-
ETA) is a method of CSA that utilizes a distributed-current-
source model. This discrete and linear solution computes a 
unique 3-D electrical source distribution by assuming that 
the smoothest of all possible inverse solutions is the most pl-
ausible, and is consistent with the assumption that neighbor-
ing neurons are active simultaneously and synchronously. The 
technique localizes the current source of cerebral activity by 
current density reconstruction and makes it possible to ob-
tain 3-D functional images.
22 This study investigated changes 
in the brain current-source density (CSD) in the high beta fre-
quency band (22-30 Hz) induced by LEV adjunctive therapy 
in patients with RPE. We compared these changes with the 
seizure frequency and the LEV dosage in these patients. 
 
Methods 
 
Subjects 
RPE patients were recruited from those attending our ep-
ilepsy clinics. Enrollment was limited to adult patients (aged 
19-60 years) whose partial-onset seizures (simple or com-
plex partial with or without secondary generalization, ac-
cording to the International League Against Epilepsy classi-
fication) were poorly controlled by AEDs. Our definition of 
RPE was partial epilepsy that is uncontrolled by two or more 
AEDs and having a frequency of at least once per month 
over 6 months before entry into the study. We included only 
right-handed persons to exclude the effects of handedness on 
the cerebral current-source distribution. Patients with progres-
sive neurological disorders, head injury, mental retardation 
(IQ<70), alcohol or drug abuse, ongoing use of any centrally 
acting medications, severe psychiatric problems, or other se-
vere medical disorders were excluded. We acquired demo-
graphic and epilepsy-related characteristics through an epil-
epsy questionnaire and the patients’ diaries. 
 
Study design 
A cohort of 31 RPE patients was enrolled in a 24-week, open-
label, prospective study. Before prescribing LEV, all patients 
gave their written informed consent to participate in the 
study. We added LEV to each patient’s current AED regimen. 
The study included a baseline phase of 12 weeks and then a 
4-week interval of titration of LEV (250 mg twice daily in 
the first 2 weeks, 500 mg twice daily in the 3rd and 4th weeks); 
thereafter, the dose regimens were adjusted individually based 
on the investigator’s clinical judgment according to the pa-
tient’s clinical response and tolerability, to obtain the best 
seizure control and tolerability. The LEV dosage was titrated 
up to 3,000 mg/day if the attacks had not subsided. Seizure 
frequency and scalp EEG were recorded, and neuropsycho-
logical tests (NPTs) were conducted before the LEV trial and 
after 24 weeks of therapy. Mood tests were conducted to cl-
arify the effect of mood on cognitive performance. EEG re-
cordings and NPTs were conducted on the same day. 
We observed LEV-induced CSD changes and determined 
whether there was any association between these changes and 
the presence of freedom from seizure or dosage of LEV. For 
the comparisons, we subdivided patients into the following 
two groups: 1) patients with seizure freedom versus those who 
were not seizure-free, and 2) patients taking at least 2,000 
mg/day LEV versus those taking less than 2,000 mg/day LEV. 
We also compared the results of NPTs conducted at 24 weeks 
with those conducted at baseline. 
 
EEG recording 
EEGs were recorded for at least 30 min in each patient using 
a 32-channel digital EEG machine (Telefactor Aurora
® EEG 
machine, Grass-Telefactor, Melbourne, Australia). All EEGs 
were recorded at 200 Hz using 19 channels based on the in-
ternational 10-20 system (Fp1, Fp2, F3, F4, C3, C4, P3, P4, 
O1, O2, F7, F8, T3, T4, T5, T6, Fz, Cz, and Pz).  
 
Current-source analysis by cross-spectral analysis 
using low-resolution brain electromagnetic 
tomography 
After recomputing to the average referential montage, five 3- 
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s, artifact-free segments were selected from the recording of 
each EEG (filtered from 1.6 to 70 Hz) from segments of the 
waking state with no epileptiform discharge. We used the data 
review and processing module in the Brain Electrical Source 
Analysis software (v. 5.1, MEGIS, Grafelfing, Germany) to 
obtain the segments. Frequency-domain analysis in the 22-
30 Hz frequency band was applied to the selected 3-s artifact-
free segments (600 sample points). LORETA-KEY (KEY In-
stitute for Brain-Mind Research, Switzerland) was used to 
calculate the intracerebral current density in the frequency-
domain analysis. 
Our version of LORETA used a three-shell spherical head 
model, registered to the Talairach human brain atlas, and the 
data available as digitized magnetic resonance images from 
the Brain Imaging Center of the Montreal Neurologic Insti-
tute.
23 The registration between the spherical and Talairach 
head geometries used the realistic EEG electrode coordinates 
reported by Towle et al.
24  
The LORETA solution space was restricted to the cortical 
gray matter and hippocampus in the Talairach atlas, as de-
fined by the corresponding digitized probability atlas. A total 
of 2,394 voxels was produced at 7-mm spatial resolution un-
der this neuroanatomical constraint.
22,25 
 
Neuropsychological tests 
All NPTs were conducted in a sound-attenuated, tempera-
ture-controlled room by a single examiner. According to the 
literature and our own clinical experience, several cognitive 
measures were selected as being particularly sensitive in epi-
lepsy patients. The following parameters were assessed: 
1) Memory function using list learning (LL), immediate 
and delayed word recall (IWR and DWR), word recognition, 
and visual reproduction based on the Memory Assessment 
Scale obtained from Psychological Assessment Resources.
26 
2)  Attention deficit using forward and backward digit spans 
from the Wechsler Memory Scale-Revised.
27 
3) Attention, visuomotor tracking abilities, and mental fl-
exibility with the Trail-Making Test, Parts A and B (TMTA 
and TMTB, respectively) from the Halstead-Reitan Battery.
28 
4) Verbal fluency using semantic fluency tests from the 
Boston Diagnostic Aphasia Examination, Third Edition.
29 
In addition, we evaluated mood states using the Beck De-
pression Inventory
30 and Beck Anxiety Inventory
31 to examine 
the effect of mood on cognitive performance. Testing sess-
ions lasted about 40 min. If a seizure occurred during a NPT, 
that test was suspended and the data were not evaluated. 
 
Statistical analysis 
Five segments of 3-s epochs were selected from a test EEG 
and a retest EEG from each patient. Thus, a total of 120 EEG 
data pairs (24 patients×5 epochs×2 conditions) were ob-
tained. Paired sample t-tests were computed for the log-tr-
ansformed LORETA power at each voxel in the 22-30 Hz 
frequency band to evaluate differences between the two con-
ditions. In all analyses, the level of statistical significance was 
set at p<0.05. These voxel-by-voxel t values were displayed 
as statistical nonparametric maps (SnPMs). 
For the NPTs, higher scores indicated better performance 
in all cognitive tests, except the TMTA and TMTB, for which 
higher scores indicated worse performance because the time 
required was defined as the dependent measure for these tests. 
Data for continuous variables are expressed as mean±SD va-
lues, and data for categorized variables are expressed as fre-
quencies (percentages). The paired t-test was used to evaluate 
the test-retest changes in neuropsychological scores induced 
by LEV adjunctive therapy. The statistical analyses were 
conducted with SPSS 12.0 (SPSS, Chicago, IL, USA), and 
results were deemed to be statistically significant at p<0.05. 
 
Results 
 
Patients 
Four of the 31 enrolled patients dropped out during the ti-
tration period due to central-nervous-system-related side ef-
Table 1. Demographic and clinical characteristics of patients (n=24)
Characteristic   
Age [years, mean (SD)]  34.6 (7.9)0 
Gender (% male)  54 
Education [years, mean (SD)]  12.9 (2.8)0 
Seizure type [no. (%)]   
Complex partial seizure  07 (29) 
Simple partial seizure plus GTCS  08 (33) 
Complex partial seizure plus GTCS  09 (38) 
Age at onset [years, mean (SD)]  20.4 (11.3) 
Duration of epilepsy [years, mean (SD)]  14.2 (10.0) 
Duration of AEDs intake [years, mean (SD)]  10.5 (7.7)0 
Number of AEDs before LEV intake [mean (SD)]  1.7 (0.6) 
Previous history of febrile convulsion [no. (%)]  06 (25) 
MRI abnormality [no. (%)]  07 (29) 
LEV dosage at last visit [mg/day, mean (SD)]  2260.4 (805.8)
Seizure frequency [per 3 months, mean (SD)]   
Baseline  13.0 (14.0) 
At 24 weeks  007.6 (14.9)* 
Epileptiform discharges on EEG [no. (%)]   
Baseline  17 (71) 
At 24 weeks  12 (50) 
Seizure freedom at 24 weeks [no. (%)]  08 (33) 
*Paired t-test, p<0.05. 
SD: standard deviation, GTCS: generalized tonic-clonic seizure,
AEDs: antiepileptic drugs, LEV: levetiracetam. 
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fects or rash. One patient stopped using LEV due to aggrava-
tion of seizures. Two patients were excluded due to unsui- 
table EEG data. A total of 24 patients completed follow-up 
EEGs and NPTs. Their demographic and clinical characte-
ristics are summarized in Table 1. After 24 weeks of treatment, 
the frequency of seizures was significantly decreased (p<0.05). 
The response rate was 54%, and seizure freedom occurred in 
33% of the patients at a mean LEV dosage of 2,260 mg/day. 
The incidence of adverse events in the last 4 weeks was 29%. 
The most common adverse events were somnolence and as-
thenia. The findings of brain magnetic resonance imaging 
(MRI) were normal in 17 of 24 patients, with the remaining 
7 patients showing the following abnormal MRI findings: 
right frontal schizencephaly, left frontal traumatic contusion, 
left hippocampal sclerosis, left hippocampal sclerosis with 
temporal arachnoid cyst, both temporal encephalitis, left tem-
Fig. 1. Statistical nonparametric maps (SnPMs) of the 22-30 Hz frequency band with an add-on trial of levetiracetam (LEV) in patients with
refractory partial epilepsy (RPE)(n=24). The current-source density (CSD) after 24 weeks of the LEV trial compared with that at baseline
was increased in the bilateral anterior cingulate gyri, left parahippocampal gyrus, and a small area of the right anterior parahippocampal
gyrus (p<0.05).  
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poroparietal arachnoid cyst, and left occipital hypoxia. 
 
Current-source analysis 
The CSD in the 22-30 Hz frequency band was increased in 
the bilateral anterior cingulate gyri, left parahippocampal 
gyrus, and a small area of the right anterior parahippocampal 
gyrus after the LEV trial (p<0.05)(Fig. 1). The CSD in a small 
area of the bilateral superior parietal gyri was higher in pa-
tients who were free of seizures (n=8) than in those who 
were not seizure-free (n=16, p<0.05)(Fig. 2A). The CSD in a 
small area of the bilateral precunei was lower in patients tak-
ing at least 2,000 mg/day LEV (n=15) than in those taking 
less than 2,000 mg/day LEV (n=9, p<0.05)(Fig. 2B). 
Neuropsychological tests 
The result of NPTs and mood tests before and after the LEV 
trial are summarized in Table 2. Performances in verbal me-
mory tests, such as LL, IWR, and DWR, were significantly 
improved after the 24-week LEV trial (p=0.007, 0.008, and 
0.023, respectively). Executive function, such as TMTA, was 
also improved at the follow-up test (p=0.008). There was no 
deterioration on any of the tests. Mood states were not signi-
ficantly changed at 24 weeks. 
 
Discussion 
 
To our knowledge, this is the first study to examine the ch-
Fig. 2. SnPMs of the 22-30 Hz frequency band with an add-on trial of LEV in patients with RPE (n=24). A: The CSD in a small area of the
bilateral superior parietal gyri was higher for seizure freedom (n=8) than for no freedom from seizures (n=16, p<0.05). B: The CSD in a small
area of the bilateral precunei was higher for an LEV dosage of at least 2,000 mg/day (n=15) than for one of less than 2,000 mg/day (n=9,
p<0.05). SnPMs: statistical nonparametric maps, LEV: levetiracetam, RPE: refractory partial epilepsy, CSD: current-source density. 
A
B 
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anges in current source induced by LEV adjunctive therapy 
in RPE patients. The CSD in the high beta frequency band 
was increased in the bilateral anterior cingulate gyri, left 
parahippocampal gyrus, and a small area of the right anterior 
parahippocampal gyrus after the LEV trial. Neither seizure 
freedom nor the dosage increment of LEV elicited mean-
ingful CSD changes. We demonstrated that verbal memory 
and executive functions had significantly improved after 24 
weeks of the LEV trial. Thus, we suggest that LEV enhances 
the activities of the neuronal networks in the prefrontal cor-
tex and left hippocampus. 
Previous studies on experimental animals and epileptic pa-
tients have shown that LEV does not impair cognitive func-
tion.
8,32 In addition, it was suggested that LEV administration 
improves neurocognitive function and quality of life in ep-
ileptic patients.
7-9,33,34 LEV is a derivative of piracetam and is 
a pyrroline-type compound. Piracetam improves learning, 
memory, and attention.
35 Drugs in this class exert protective 
effects against brain insults,
36 promote the efficacy of the 
higher integration mechanisms in the brain, and improve men-
tal functions such as learning and memory.
37 Our patients with 
RPE showed improved cognitive performance after 24 weeks 
of LEV administration. These findings are consistent with 
those of Piazzini et al.
8 and Zhou et al.
9 
Digital EEG analyses of the neurocognitive effects of ep-
ilepsy and AEDs have been conducted previously. We found 
three studies that sought to correlate digital EEG analyses with 
the neurocognitive effects of AEDs drugs in healthy volun-
teers.
38-40 In one study, both CBZ and gabapentin (GBP) were 
shown to reduce the peak frequency of the posterior alpha 
rhythm, with the change being larger for CBZ than for GBP. 
Among the NPTs, the digital symbol test and Stroop test 
were affected by AEDs.
38 In another study, both oxcarbaze-
pine (OXC) and phenytoin slowed the EEG peak frequency 
and increased the relative theta and delta powers. Significant 
cognitive effects primarily appeared in measures of motor 
speed and reaction time for both AEDs. The only significant 
difference between AEDs was for mood, favoring OXC.
39 In 
another study, TPM produced no significant change in any 
EEG measure from the averaged occipital electrodes, alth-
ough several target NPTs revealed negative effects of TPM. 
However, GBP slowed the peak and median frequency EEG 
measures and increased the percentage of theta and delta ac-
tivities.
40 
Another study with a very similar design to ours
41 ana-
lyzed the occipital EEG rhythms using the fast Fourier trans-
form in 28 patients with pharmacoresistant epilepsy. LEV 
adjunctive therapy did not slow EEG rhythms over the oc-
cipital regions at 2 months after the initiation of therapy and 
achieving the end-dose, or at 4 months after achieving plateau 
dosing as compared with baseline measures. In other words, 
there were no changes in alpha, theta, and delta bands. In ad-
dition, the percentage of activity in the beta band increased. 
Our study used the distributed source model of CSA, which 
has not previously been applied to test the cognitive effects 
of AEDs. 
Task-related high-frequency oscillations include two func-
tionally distinctive components. Complex cognitive tasks, 
such as language processing, are associated with neuronal 
oscillation at frequencies of 25-35 Hz.
18 In a study using EEG 
and magnetoencephalogram experiments, spectral responses 
of about 30 Hz were specifically induced by a language pro-
cess using meaningful words but not by meaningless non-
words.
15 In contrast, the processing of simple stimuli affects 
the spectral power in the higher-frequency range of the gamma 
band. Tones, moving bars, and simple repetitive movements 
are usually accompanied by spectral activity at 40 Hz or ab-
ove.
19 The increase in high-frequency synchronization may 
indicate a general mechanism enabling transient associations 
between neuronal assemblies. 
Regarding our results, the CSD in the high beta frequency 
band was increased in anatomical structures relevant to the 
improvement in NPTs. Since the left hippocampus is func-
tionally important for verbal memory, the increase in CSD in 
the left parahippocampal gyrus may reflect the improvement 
in verbal memory function. The cingulate gyrus is a part of 
the prefrontal cortex, which is functionally important for ex-
Table 2. Neuropsychological and mood outcomes of patients
(n=24) 
Baseline
At 24  
weeks  Battery item 
Mean (SD)  Mean (SD) 
Significance
(p)* 
List learning  051.3 (11.7)  056.7 (10.0)  0.007 
Immediate word recall  008.9 (2.4)0  010.4 (1.9)0  0.008 
Delayed word recall  009.0 (2.5)0  010.2 (2.0)0  0.023 
Word recognition  011.5 (0.8)0  011.7 (1.2)0  0.657 
Visual reproduction  006.2 (2.9)0  006.9 (2.5)0  0.128 
Digit span, forward  005.9 (2.3)0  006.3 (3.2)0  0.420 
Digit span, backward  005.1 (2.5)0  005.5 (2.9)0  0.399 
Trail-Making Test, 
  part A, time (s) 
045.9 (26.9) 
 
035.5 (15.6) 
 
0.008 
 
Trail-Making Test, 
  part B, time (s) 
113.7 (52.4) 
 
103.8 (66.9) 
 
0.453 
 
Verbal fluency  010.9 (5.1)0  012.9 (6.5)0  0.146 
BDI  017.1 (10.4)  014.1 (11.2)  0.124 
BAI  015.2 (11.0)  011.9 (11.5)  0.078 
Higher scores indicate better performance in all cognitive tests
(except for the Trail-Making Test) and worse condition in the
mood tests. 
*Paired t-test for comparison between baseline and at 24 weeks 
of LEV trial. 
BDI: Beck Depression Inventory, BAI: Beck Anxiety Inventory. 
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ecutive tasks, and so the increase in CSD in the bilateral an-
terior cingulated gyri suggests improved executive function.
42 
Neither seizure freedom nor the dosage increment of LEV 
elicited meaningful CSD changes. The changes in CSD sug-
gest a stimulatory effect of LEV on cognition. 
The present study has some limitations. We used fewer 
than the 32 available channels, which could have resulted in 
some localization errors, particularly in the basal aspects of 
the brain.
43 The localization accuracy for LORETA has been 
shown to increase when using from 25 to around 89 elec-
trodes, and then to plateau thereafter.
44 However, a lower 
number of electrodes may be sufficient for the SnPM me-
thod of LORETA to localize the areas of increased activity.
45,46 
It has also been observed that current-source estimation us-
ing LORETA in a three-shell head model is similar when 
using between 19 and 46 scalp electrodes when the electrodes 
are evenly distributed.
44 Our version of LORETA used a three-
shell spherical head model instead of a realistic head model. 
The errors associated with using a spherical model with a 
small number of electrodes range from 10 to 20 mm.
43,47,48 
Using a greater number of more closely spaced electrodes 
would have enhanced the topographical resolution and pro-
duced better current-source localization results. 
There were also several limitations with regard to the NPTs. 
First, the sample of patients was relatively small. Second, 
because this was not a randomized, placebo-controlled study, 
we cannot exclude a placebo effect of LEV on cognition. 
Third, because LEV was added to other AED regimes, we 
cannot rule out the impact of other AEDs on cognition. Fur-
ther cognitive studies of LEV based on blind or placebo-con-
trolled, monotherapy trials with larger numbers of patients are 
needed to obtain clearer and more reliable answers to these 
issues. 
 
Acknowledgements 
The authors thank Geum-Ye Bae, who is a neuropsychologist, for con-
ducting the neuropsychological tests, and Seokwon Jung, who is an EEG 
technician, for processing the EEG data. 
 
REFERENCES 
1. Park SP, Kwon SH. Cognitive effects of antiepileptic drugs. J Clin 
Neurol 2008;4:99-106. 
2. Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral 
effects of antiepilepsy drugs. Neuropsychol Rev 2007;17:413-425. 
3. Lee HW, Jung DK, Suh CK, Kwon SH, Park SP. Cognitive effects of 
low-dose topiramate monotherapy in epilepsy patients: A 1-year fol-
low-up. Epilepsy Behav 2006;8:736-741. 
4. Park SP, Hwang YH, Lee HW, Suh CK, Kwon SH, Lee BI. Long-
term cognitive and mood effects of zonisamide monotherapy in epile-
psy patients. Epilepsy Behav 2008;12:102-108. 
5. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik 
I. Levetiracetam for partial seizures: results of a double-blind, ran-
domized clinical trial. Neurology 2000;55:236-242. 
6. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U; Leve-
tiracetam N01057 Study Group. Placebo-controlled study of levetir-
acetam in idiopathic generalized epilepsy. Neurology 2007;69:1751-
1760. 
7. Meador KJ, Gevins A, Loring DW, McEvoy LK, Ray PG, Smith ME, 
et al. Neuropsychological and neurophysiologic effects of carbama-
zepine and levetiracetam. Neurology 2007;69:2076-2084. 
8. Piazzini A, Chifari R, Canevini MP, Turner K, Fontana SP, Canger R. 
Levetiracetam: an improvement of attention and of oral fluency in 
patients with partial epilepsy. Epilepsy Res 2006;68:181-188. 
9. Zhou B, Zhang Q, Tian L, Xiao J, Stefan H, Zhou D. Effects of leve-
tiracetam as an add-on therapy on cognitive function and quality of life 
in patients with refractory partial seizures. Epilepsy Behav 2008;12: 
305-310. 
10. Neyens LG, Alpherts WC, Aldenkamp AP. Cognitive effects of a new 
pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog 
Neuropsychopharmacol Biol Psychiatry 1995;19:411-419. 
11. Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psy-
chiatric impact of add-on titration of pregabalin versus levetiracetam: 
a comparative short-term study. Epilepsy Behav 2006;9:424-431. 
12. Aldenkamp AP, Overweg J, Gutter T, Beun AM, Diepman L, Mulder 
OG. Effect of epilepsy, seizures and epileptiform EEG discharges on 
cognitive function. Acta Neurol Scand 1996;93:253-259. 
13. Coq JO, Xerri C. Acute reorganization of the forepaw representation 
in the rat SI cortex after focal cortical injury: neuroprotective effects 
of piracetam treatment. Eur J Neurosci 1999;11:2597-2608. 
14. Kristeva-Feige R, Feige B, Makeig S, Ross B, Elbert T. Oscillatory 
brain activity during a motor task. Neuroreport 1993;4:1291-1294. 
15. Pulvermüller F, Eulitz C, Pantev C, Mohr B, Feige B, Lutzenberger 
W, et al. High-frequency cortical responses reflect lexical processing: 
an MEG study. Electroencephalogr Clin Neurophysiol 1996;98:76-85. 
16. Bhattacharya J, Petsche H, Pereda E. Long-range synchrony in the 
gamma band: role in music perception. J Neurosci 2001;21:6329-6337. 
17. Tallon C, Bertrand O, Bouchet P, Pernier J. Gamma-range activity 
evoked by coherent visual stimuli in humans. Eur J Neurosci 1995;7: 
1285-1291. 
18. Pulvermüller F. Hebb’s concept of cell assemblies and the psycho-
physiology of word processing. Psychophysiology 1996;33:317-333. 
19. Pantev C. Evoked and induced gamma-band activity of the human 
cortex. Brain Topogr 1995;7:321-330. 
20. Fell J, Fernández G, Klaver P, Elger CE, Fries P. Is synchronized 
neuronal gamma activity relevant for selective attention? Brain Res 
Brain Res Rev 2003;42:265-272. 
21. Koles ZJ. Trends in EEG source localization. Electroencephalogr Clin 
Neurophysiol 1998;106:127-137. 
22. Pascual-Marqui RD, Michel CM, Lehmann D. Low resolution elec-
tromagnetic tomography: a new method for localizing electrical ac-
tivity in the brain. Int J Psychophysiol 1994;18:49-65. 
23. Talairach J, Tournoux P. Co-planar sterotaxic atlas of the human brain: 
3-dimensional proportional system-an approach to cerebral imaging. 
New York: Thieme Medical Publisher, 1988. 
24. Towle VL, Bolaños J, Suarez D, Tan K, Grzeszczuk R, Levin DN, et 
al. The spatial location of EEG electrodes: locating the best-fitting 
sphere relative to cortical anatomy. Electroencephalogr Clin Neuro-
physiol 1993;86:1-6. 
25. Pascual-Marqui RD. Review of methods for solving the EEG inverse 
problem. Interantional Journal of Bioelectromagnetism 1999;1:75-86. 
26. Williams JM. Memory Assessment Scales profesional manual. Od-
essa, FL: Psychological Assessment Resources, 1991. 
27. Wechsler D. Wechsler Memory Scale-Revised manual. San Antonio, 
TX: Psychological Corp., 1987. 
28. Reitan RM, Wolfson D. The Halstead-Retan Neuropsychological Test 
Battery: theory and clinical interpretation. 2nd ed. Tucson, AZ: Neu-
ropsychology Press, 1993. 
29. Goodglass H, Kaplan E, Barresi B. Boston Diagnostic Aphasia Ex-
amination. 3rd ed. (BDAE-3). San Antonio, TX: Psychhological Corp.,  
 
 
 
 
Park SP and Kwon OY 
  www.thejcn.com 185
2000. 
30. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory 
for measuring depression. Arch Gen Psychiatry 1961;4:561-571. 
31. Beck AT, Steer RA. Manual for the Beck Anxiety Inventory. San An-
tonio, TX: Psychological Corp., 1990. 
32. Wagner GL, Wilms EB, Van Donselaar CA, Vecht ChJ. Levetirace-
tam: preliminary experience in patients with primary brain tumours. 
Seizure 2003;12:585-586. 
33. Mecarelli O, Vicenzini E, Pulitano P, Vanacore N, Romolo FS, Di 
Piero V, et al. Clinical, cognitive, and neurophysiologic correlates of 
short-term treatment with carbamazepine, oxcarbazepine, and levetira-
cetam in healthy volunteers. Ann Pharmacother 2004;38:1816-1822. 
34. Helmstaedter C, Witt JA. The effects of levetiracetam on cognition: a 
non-interventional surveillance study. Epilepsy Behav 2008;13:642-
649. 
35. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive im-
pairment. Cochrane Database Syst Rev 2000:CD001011. 
36. Schindler U. Pre-clinical evaluation of cognition enhancing drugs. 
Prog Neuropsychopharmacol Biol Psychiatry 1989;13 Suppl:S99-S115. 
37. Genton P, Van Vleymen B. Piracetam and levetiracetam: close struc-
tural similarities but different pharmacological and clinical profiles. 
Epileptic Disord 2000;2:99-105. 
38. Salinsky MC, Binder LM, Oken BS, Storzbach D, Aron CR, Dodrill 
CB. Effects of gabapentin and carbamazepine on the EEG and cogni-
tion in healthy volunteers. Epilepsia 2002;43:482-490. 
39. Salinsky MC, Spencer DC, Oken BS, Storzbach D. Effects of oxcar-
bazepine and phenytoin on the EEG and cognition in healthy volun-
teers. Epilepsy Behav 2004;5:894-902. 
40. Salinsky M, Storzbach D, Oken B, Spencer D. Topiramate effects on 
the EEG and alertness in healthy volunteers: a different profile of an-
tiepileptic drug neurotoxicity. Epilepsy Behav 2007;10:463-469. 
41. Veauthier J, Haettig H, Meencke HJ. Impact of levetiracetam add-on 
therapy on different EEG occipital frequencies in epileptic patients. 
Seizure 2009;18:392-395. 
42. Devinsky O, D’Esposito M. Neurology of cognitive and behavioral 
disorders. 1st ed. New York: Oxford, 2004:275-329. 
43. Krings T, Chiappa KH, Cuffin BN, Cochius JI, Connolly S, Cosgrove 
GR. Accuracy of EEG dipole source localization using implanted 
sources in the human brain. Clin Neurophysiol 1999;110: 106-114. 
44. Michel CM, Murray MM, Lantz G, Gonzalez S, Spinelli L, Grave de 
Peralta R. EEG source imaging. Clin Neurophysiol 2004;115:2195-
2222. 
45. Zumsteg D, Friedman A, Wennberg RA, Wieser HG. Source locali-
zation of mesial temporal interictal epileptiform discharges: correlation 
with intracranial foramen ovale electrode recordings. Clin Neurophy-
siol 2005;116:2810-2818. 
46. Zumsteg D, Friedman A, Wieser HG, Wennberg RA. Propagation of 
interictal discharges in temporal lobe epilepsy: correlation of spatio-
temporal mapping with intracranial foramen ovale electrode record-
ings. Clin Neurophysiol 2006;117:2615-2626. 
47. Merlet I, Garcia-Larrea L, Grégoire MC, Lavenne F, Mauguiére F. 
Source propagation of interictal spikes in temporal lobe epilepsy. Cor-
relations between spike dipole modelling and [18F]fluorodeoxy-glu-
cose PET data. Brain 1996;119:377-392. 
48. Cuffin BN, Schomer DL, Ives JR, Blume H. Experimental tests of 
EEG source localization accuracy in realistically shaped head models. 
Clin Neurophysiol 2001;112:2288-2292. 
 
 